RNA interference (RNAi) is triggered by the presence of a double-stranded RNA (dsRNA) in the cell, and results in the silencing of homologous gene expression by the specific degradation of an mRNA containing the same sequence. dsRNA-mediated RNAi can be used in a wide variety of eucaryotes to induce the sequence-specific inhibition of gene expression. Synthetic 21-23 nucleotide (nt) small interfering RNAs (siRNAs) with 2-nt 3 0 overhangs were recently found to mediate efficient sequence-specific mRNA degradation in mammalian cells. Here, we show that synthetic siRNAs targeted against the viral structural Env proteins encoded by HIV-1 can specifically suppress the expression of HIV-1 genes. The siRNA-mediated RNAi also had advantages over antisense RNA-mediated inhibition, in terms of both the ease of designing effective antiviral agents and their potency. Especially, our best env-specific siRNAs, E7145 targeted to the central region of the V3 loop and E7490 targeted to the CD4 binding site of conserved regions on gp120, significantly inhibited the HIV-1 gene expression. Furthermore, E7145 and E7490 were effective against HIV-1 NL4-3 replication in PBMCs for a relatively long time (14 days). Therefore, the use of synthetic siRNAs provides a simple, rapid, and costeffective tool for new anti-HIV-1 gene therapeutics. Gene Therapy (2003) Keywords: RNA interference; small interfering RNAs; HIV-1 env genes; antiviral RNAi technology; PBMCs RNA interference (RNAi) or RNA silencing is an evolutionarily conserved phenomenon in which double-stranded RNA (dsRNA) induces the homologydependent degradation of the cognate mRNA.
RNA interference (RNAi) or RNA silencing is an evolutionarily conserved phenomenon in which double-stranded RNA (dsRNA) induces the homologydependent degradation of the cognate mRNA. 1 RNAi is initiated by the RNase III-like nuclease Dicer, which promotes the processive cleavage of long dsRNAs into 21-to 23-nucleotide (nt) small interfering RNAs (siRNAs) with 2-nt 3 0 overhangs. [2] [3] [4] [5] [6] Subsequently, the siRNAs are incorporated into an RNA-induced silencing complex (RISC), identified in Drosophila, and the protein-RNA effector nuclease complex recognizes and destroys the target mRNAs. [7] [8] [9] It was recently found that the transfection of synthetic 21-23 nt siRNAs with 2-nt 3 0 overhangs into mammalian cells effectively inhibits the expression of the endogenous genes in a sequence-specific manner. [10] [11] [12] These small RNA duplexes, which are chemically synthesized mimics of Dicer products, are presumably incorporated into RISC and target their cognate substrates for degradation. Lee et al 13 have reported the inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the expression of small interfering RNAs targeted against HIV-1 rev in human cells. In addition, Jacque et al 14 demonstrated the utility of siRNA-mediated RNAi for modulating HIV replication by synthetic siRNAs or plasmid-derived siRNAs targeted to various regions of the HIV-1 genome (TAR, vif, nef).
We previously reported that long dsRNAs effectively inhibit HIV-1 replication in HIV-1 infected cells. 15 However, the utility of these long dsRNAs appeared to be limited, due to the nonspecific inhibitory response resulting from the activation of a dsRNA-dependent protein kinase (PKR) and a 2 0 -5 0 -oligoadenylate (2-5A) synthetase. 16, 17 A 21-23 nt siRNA can mediate RNAi, but bypasses the nonspecific response induced by longer dsRNAs.
In this study, we have designed four siRNAs against several regions of the HIV-1 env genes to apply a more useful antiviral RNAi technology. The mRNA targets for siRNAi were selected from the middle of the env regions in the HIV-1 genome, since we previously found that 531 bp (7070-7600) E2-dsRNAs complementary to the env mRNA-containing V3 loop and the major CD4 binding domain sequence of gp 120 were more effective inhibitors of HIV-1 replication than those targeted to the gag gene. 15 Furthermore, the envelope protein (Env) of HIV-1 mediates functions that are critical to the viral life cycle, including the viral attachment to target cells and the fusion of viral and cellular membranes.
To investigate the siRNA-mediated silencing, we initially synthesized four siRNAs against the middle of the env regions in the HIV-1 genome (Figure 1 ). For in vitro transcription, DNA template oligonucleotides with a T7 promoter sequence (TAATACGACTCACTATAG) were designed to produce 22-nt siRNAs. The siRNA sequences of the form GN 18 CN 2 were selected for each target because efficient T7 RNA polymerase initiation requires a G as the first nt of each RNA. 18 Sense and antisense RNAs were synthesized with T7 RNA polymerase separately in vitro from a dsDNA template and were annealed to each other to create a 22-nt siRNA duplex, with 2-nt ribo-uridine 3 0 overhangs at each end. To test whether siRNAs can specifically inhibit HIV-1 gene expression, we cotransfected COS cells with HIV-1 proviral expression plasmids (pNL4-3) 19 and either a synthetic siRNAs duplex or a single-stranded RNA corresponding to HIV-1 env (Figure 2a ). When we examined the cellular uptake of the fluorescently labeled siRNAs, prepared with a Silencert siRNA Labeling kit (Ambion, TX, USA), with several kinds of transfection reagents (Lipofectaminet 2000, 12, 18 Lipofectin, and Oligofectamine) by the FACS Calibur and CellQuest software, the FITC-labeled siRNAs encapsulated with Lipofectaminet 2000 strongly associated with the target cells (data not shown). Cotransfection of plasmids (pNL4-3) and siRNAs was carried out using Lipofectaminet 2000. The virus production in the culture supernatant was assessed by an HIV-1 p24 CLEIA assay 20 at 3 days, and was related to the amount produced in the absence of the siRNA. The four env-specific siRNAs all effectively inhibited HIV-1 gene expression, with a wide range of activities. In cells transfected with E7145, targeted to the central region of the V3 loop, or E7490, targeted to the CD4 binding site of conserved regions on gp120, the p24 antigen expression was reduced to nearbackground levels, as shown in Figure 2a . Interestingly, the inhibition mediated by the siRNA E7457 was higher than that seen with the siRNA E7361 in the targeting of an intersubunit disulfide bond on gp120. The sense RNAs were ineffective in reducing the amount of p24 antigen, whereas the antisense RNAs modestly reduced 0 overhangs, and are numbered according to the position of the first nucleotide of the sense strand. The 18-nt sense strand corresponding to the functional six amino acids is completely homologous to the target HIV-1 sequence. To generate siRNAs in vitro, we designed DNA template oligonucleotides with a T7 promoter sequence. The templates corresponding to the sense and antisense sequences of the target gene were mixed in equimolar amounts, heated to 951C for 5 min, and then gradually cooled to room temperature in TE buffer (10 mM Tris (pH 8.0), 0.1 mM EDTA). In vitro transcription was carried out by using the AmpliScribe Transcription Kit (Epicentre Technologies, WI, USA) with 1 mg of DNA template. Following the transcription reaction, equimolar quantities of the sense and antisense 22-nt RNAs generated in separate reactions were annealed by mixing and heating at 951C for 5 min, followed by a 1-h incubation at 371C to obtain the T7 siRNA. . A 48-ml aliquot of RPMI-1640 medium without serum was mixed with 2 ml of Lipofectaminet 2000 per dish, and the mixture was preincubated for 5 min at room temperature. During this incubation, another 50 ml aliquot of RPMI-1640 medium was mixed with pNL4-3 (0.1 mg) and the various single-stranded or double-stranded siRNAs (0.5 mg) as indicated. The two mixtures were combined and incubated for 20 min at room temperature for complex formation. The entire mixture was then added to the cells. The plasmid pNL4-3 is an HIVbased infectious vector, which was purified with the plasmid Maxi-prep Kit (SIGMA, St Louis, MO, USA), followed by phenol extraction and ethanol precipitation. At 3 days post transfection, p24 Gag protein production was detected by the HIV-1 p24 CLEIA assay (Lumipulse; Fujirebio Inc., Tokyo, Japan). (b) Dose-dependence of env-specific siRNAs. COS cells were cotransfected with pNL4-3 (0.1 mg) and various amounts of siRNAs (0.02-0.5 mg), using Lipofectaminet 2000. After a 72-h incubation, p24 antigen production was monitored in the culture supernatants with the HIV-1 p24 CLEIA assay. Mock-transfected COS cells served as the positive control (POS).
Specific inhibition of HIV-1 gene expression by siRNA-mediated interference W-S Park et al the amount of p24 antigen. However, the four siRNAs directed against HIV-1 env effectively inhibited HIV-1 gene expression by more than B1.5-fold, relative to the antisense RNAs. Importantly, the specificity of this effect was demonstrated by the finding that a nonhomologous control siRNA had no significant effect on HIV-1 suppression.
To characterize the siRNA-mediated RNAi reaction further, we tested the dose-dependent effect of the siRNAs. COS cells were cotransfected with the various concentrations (0.02-0.5 mg) of the siRNAs and pNL4-3, using Lipofectaminet 2000 (Figure 2b ). The control siRNA did not induce any significant suppression of HIV-1 gene expression in this dose-dependent assay. The four env-specific siRNAs induced the RNA interferencemediated HIV-1 inhibition in a dose-responsive manner. In particular, 0.5 mg of E7490 showed a significantly high inhibitory effect on HIV-1 gene expression. Therefore, these results suggest that siRNAs inhibit HIV-1 gene expression in a sequence-specific manner.
We next examined the inhibition of HIV-1 gene expression at the mRNA level to identify the contribution of the siRNA-mediated specific RNA interference. Total RNA was purified from COS cells that had been transfected with the homologous four siRNAs or the nonhomologous control siRNAs and pNL4-3, and equal amounts of RNA were subjected to a polymerase chain reaction with reverse transcription (RT-PCR) analysis. The RT-PCR analysis of the HIV-1 mRNA was carried out using HIV-1 env-specific primers with concomitant amplification of G3PDH. As shown in Figure 3 , the percentage decrease was B83% for all four env siRNAs, as compared with the levels of HIV-1 mRNA in cells transfected only with the plasmid. Especially, the treatment with either of the two best siRNAs, E7145 or E7490, induced a marked reduction in the levels of HIV-1 mRNA relative to the levels in cells that were transfected with control siRNA or plasmid-only. Therefore, the siRNA-mediated RNAi is fully functional and sequence-specifically inhibits HIV-1 gene expression.
Next, to clarify the ability of siRNA to inhibit viral replication in HIV-1 infected cells, we first used the HeLa-CD4 þ cell line. Sense, antisense, and siRNAs (0.5 mg), encapsulated with Lipofectaminet 2000, were each transfected into HeLa-CD4 þ cells. Following a 4-h incubation at 371C, the cells were inoculated with the HIV-1 NL4-3 virus. As shown in Figure 4 , the two best siRNAs, E7145 and E7490, significantly inhibited HIV-1 replication, similar to the level obtained with the COS cell-based assay. The four siRNAs targeted to the HIV-1 env genes effectively inhibited HIV-1 replication more than B2-fold relative to the antisense RNAs. In contrast, the four sense RNAs showed only slight suppression of the p24 expression. These results indicate that the four siRNAs targeted to the HIV-1 env genes have potent and specific inhibitory effects on HIV-1 replication. Also, they suggest that the siRNA is more effective in targeting the HIV-1 genes than the antisense RNA.
In addition, we examined whether the siRNAs could also inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMCs), which are natural targets for HIV-1 infection. The env-specific siRNA inhibitory effect and its persistence on viral replication were investigated in HIV-1 infected PBMCs over a 14 day period. PHAstimulated PBMCs were infected with the HIV-1 NL4-3 virus, in the presence of the siRNAs E7145 or E7490. In the cells treated with the env-specific siRNAs, E7145 and E7490, the p24 antigen expression was effectively reduced as compared to the untreated cells (Figure 5a) . Moreover, E7145 and E7490 were also effective against HIV-1 NL4-3 replication for a relatively long time (14 days). Next, to assess the effects of the single-stranded RNA and the siRNA duplexes in PBMCs, we compared the inhibitory effects of siRNAs targeted to the HIV-1 env gene with those of the corresponding sense and antisense RNAs at 10 days post infection (Figure 5b ). The siRNA Specific inhibition of HIV-1 gene expression by siRNA-mediated interference W-S Park et al duplexes directed against the HIV-1 env genes more effectively inhibited HIV-1 replication relative to the single-stranded RNA. Also, the siRNAs E7145 and E7490 directed against env reduced the p24 antigen levels in a dose-dependent manner (data not shown). Taken together, our results indicate that the siRNA-mediated RNAi is fully functional in cells naturally targeted by HIV-1 infection.
In this report, we have shown that the synthetic siRNAs targeted to the HIV-1 env gene can effectively and specifically inhibit HIV-1 gene expression by reducing the viral mRNA expression. Furthermore, the siRNA duplexes were more potent inhibitors than the antisense RNAs. Our best siRNA candidates, E7145 targeted to the central region of the V3 loop and E7490 targeted to the CD4 binding site of the conserved regions on gp120, significantly inhibited the HIV-1 gene expression. Especially, E7145 and E7490 were effective against HIV-1 NL4-3 replication in PBMCs for a relatively long time (14 days). Thus, we suggest that siRNA-mediated RNA interference targeted to the HIV-1 env gene can be developed as a new class of potential therapeutics for AIDS.
In particular, use of T7 RNA polymerase synthesized siRNA to obtain large amounts of siRNAs offers advantages of simplicity and economical efficiency. These approaches will be crucial for overcoming limited availability of synthetic siRNA technology for gene silencing in mammalian cells; furthermore, it will be useful for extending the potential of siRNA to therapies for HIV infection. However, apart from advantages offered by siRNA for viral infection control, bottlenecks including dosage for actual clinical situations could challenge future researchers in the clinical field. Notwithstanding, simplicity of siRNA-mediated RNAi technology may enable 'combination therapy' along with several siRNAs targeted to different regions of env or HIV-1 specific genes. They could constitute a new approach to preventing emergence of drug-resistant viruses. Moreover, further development and modifications of viral vector-based systems capable of expressing active env-siRNA will assist establishment of an effective clinical application against HIV-1.
